Kite Pharma, Inc.
DelistedCIK 1510580fmd_0A0PB25HW1MWGTB1QM2F4YBM11Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2012 to Jun 30, 2017, 19 periods
| Line item | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|---|---|---|---|---|
| Total revenues | – | – | 0 | 17 | 22 |
| Research and development | 2 | 5 | 23 | 76 | 198 |
| Total operating expenses | 3 | 6 | 37 | 121 | 295 |
| Operating income | (3) | (6) | (37) | (104) | (273) |
| Interest expense | 0 | 0 | 6 | 0 | 0 |
| Interest and investment income | 0 | 0 | 0 | 2 | 4 |
| Other non-operating income (expense) | 0 | 0 | (6) | 2 | 3 |
| Income before taxes | – | – | (43) | (102) | (270) |
| Income tax expense | – | 0 | 0 | 0 | (3) |
| Net income from continuing operations | – | – | (43) | (102) | (267) |
| Net income | (3) | (6) | (43) | (102) | (267) |
| Net income to common shareholders | (3) | (8) | (44) | (102) | (267) |